



July 15, 2022

### **APL 22-010 CANCER BIOMARKER TESTING**

Dear Provider,

The Department of Health Care Services (DHCS) released All Plan Letter (APL) 22-010 to provide information regarding coverage requirements for using Cancer Biomarker Testing as required by Senate Bill (SB) 535.

KHS is required to cover medically necessary biomarker testing for members with:

- Advanced or metastatic stage 3 or 4 cancer
- Cancer progression or recurrence in the member with advanced or metastatic stage 3 or 4 cancer

If the biomarker test is associated with a federal Food and Drug Administration (FDA) approved therapy, a prior authorization is not needed. If the biomarker test is not associated with an FDA-approved cancer therapy for advanced or metastatic stage 3 or 4 cancer, an authorization may be required. Please refer to the KHS prior authorization list to determine if an authorization is needed. You can search the list by using Ctrl + F on your keyboard and entering in the applicable CPT code. If the code is found on the list, an authorization is required. If the code is not found on the list and it is a Medi-Cal recognize code, then a prior authorization is not required.

Additional information:

APL 22-010:

<https://www.dhcs.ca.gov/formsandpubs/Documents/MMCDAPLsandPolicyLetters/APL2022/APL22-010.pdf>

Information on stages of cancer can be found here:

<https://www.cancer.net/navigating-cancer-care/diagnosing-cancer/stages-cancer>

KHS posts all bulletins on the KHS website, [www.kernfamilyhealthcare.com](http://www.kernfamilyhealthcare.com), choose Provider, then Bulletins.

For any questions, please contact your Provider Relations Representative at 1-800-391-2000.

Sincerely,

Melissa McGuire  
Deputy Director of Provider Network  
Kern Health Systems